These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 29039611)

  • 1. Altered expression of different GalNAc‑transferases is associated with disease progression and poor prognosis in women with high-grade serous ovarian cancer.
    Sheta R; Bachvarova M; Plante M; Gregoire J; Renaud MC; Sebastianelli A; Popa I; Bachvarov D
    Int J Oncol; 2017 Dec; 51(6):1887-1897. PubMed ID: 29039611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation.
    Wang ZQ; Bachvarova M; Morin C; Plante M; Gregoire J; Renaud MC; Sebastianelli A; Bachvarov D
    Oncotarget; 2014 Jan; 5(2):544-60. PubMed ID: 24504219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The polypeptide GALNT6 Displays Redundant Functions upon Suppression of its Closest Homolog GALNT3 in Mediating Aberrant O-Glycosylation, Associated with Ovarian Cancer Progression.
    Sheta R; Bachvarova M; Macdonald E; Gobeil S; Vanderhyden B; Bachvarov D
    Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31071912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A metabolic labeling approach for glycoproteomic analysis reveals altered glycoprotein expression upon GALNT3 knockdown in ovarian cancer cells.
    Sheta R; Woo CM; Roux-Dalvai F; Fournier F; Bourassa S; Droit A; Bertozzi CR; Bachvarov D
    J Proteomics; 2016 Aug; 145():91-102. PubMed ID: 27095597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 7. The mucin-type glycosylating enzyme polypeptide N-acetylgalactosaminyltransferase 14 promotes the migration of ovarian cancer by modifying mucin 13.
    Wang R; Yu C; Zhao D; Wu M; Yang Z
    Oncol Rep; 2013 Aug; 30(2):667-76. PubMed ID: 23708057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upregulation of Abelson interactor protein 1 predicts tumor progression and poor outcome in epithelial ovarian cancer.
    Zhang J; Tang L; Chen Y; Duan Z; Xiao L; Li W; Liu X; Shen L
    Hum Pathol; 2015 Sep; 46(9):1331-40. PubMed ID: 26193797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of Placenta Growth Factor Is Associated with Unfavorable Prognosis of Advanced-Stage Serous Ovarian Cancer.
    Meng Q; Duan P; Li L; Miao Y
    Tohoku J Exp Med; 2018 Apr; 244(4):291-296. PubMed ID: 29643276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma.
    Zhang W; Niu C; He W; Hou T; Sun X; Xu L; Zhang Y
    Tumour Biol; 2016 May; 37(5):6239-54. PubMed ID: 26615423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
    Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
    Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant Expression of Anaplastic Lymphoma Kinase in Ovarian Carcinoma Independent of Gene Rearrangement.
    Tang S; Yang F; Du X; Lu Y; Zhang L; Zhou X
    Int J Gynecol Pathol; 2016 Jul; 35(4):337-47. PubMed ID: 27271776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defective expression of Protein 4.1N is correlated to tumor progression, aggressive behaviors and chemotherapy resistance in epithelial ovarian cancer.
    Xi C; Ren C; Hu A; Lin J; Yao Q; Wang Y; Gao Z; An X; Liu C
    Gynecol Oncol; 2013 Dec; 131(3):764-71. PubMed ID: 23994105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
    Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
    J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCAT1 expression associates with ovarian cancer progression: possible implications in altered disease metabolism.
    Wang ZQ; Faddaoui A; Bachvarova M; Plante M; Gregoire J; Renaud MC; Sebastianelli A; Guillemette C; Gobeil S; Macdonald E; Vanderhyden B; Bachvarov D
    Oncotarget; 2015 Oct; 6(31):31522-43. PubMed ID: 26372729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
    Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
    Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
    Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
    BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EphA8 is a prognostic marker for epithelial ovarian cancer.
    Liu X; Xu Y; Jin Q; Wang W; Zhang S; Wang X; Zhang Y; Xu X; Huang J
    Oncotarget; 2016 Apr; 7(15):20801-9. PubMed ID: 26989075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low levels of ADAM23 expression in epithelial ovarian cancer are associated with poor survival.
    Ma R; Tang Z; Sun K; Ye X; Cheng H; Chang X; Cui H
    Pathol Res Pract; 2018 Aug; 214(8):1115-1122. PubMed ID: 29921495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Over-Expression of TBL1XR1 Indicates Poor Prognosis of Serous Epithelial Ovarian Cancer.
    Ma M; Yu N
    Tohoku J Exp Med; 2017 Mar; 241(3):239-247. PubMed ID: 28344213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.